India · Delayed Price · Currency is INR Sudarshan Chemical Industries Earnings Call Transcripts
Fiscal Year 2027
-
Q1 FY27 delivered robust revenue and EBITDA growth, with strong margin improvement and significant debt reduction. Guidance remains unchanged due to geopolitical uncertainties, but ongoing cost reduction and value capture initiatives are expected to drive further gains.
Fiscal Year 2026
-
Integration of acquired pigment businesses drove robust Q4 and FY26 results, with business EBITDA exceeding targets and net debt reduced. Despite higher input costs from geopolitical tensions, margin discipline and value capture initiatives support a positive outlook for FY27.
-
Q3 was pressured by weak demand and acquired-customer destocking, while cost savings limited losses. Management sees buying recovery and targets EUR 30–40 million of inventory reduction, supporting cash flow but temporarily weighing on reported EBITDA.
-
Acquisition integration is progressing, but Q2 was impacted by weak global demand and high customer inventories, leading to revised FY26 EBITDA guidance. Strong recovery is expected in Q4 as inventories normalize and demand returns.
-
Integration of acquired pigment businesses has stabilized operations and expanded the global footprint, with Q1 revenue at INR 2,507 crore and Adjusted EBITDA at INR 165 crore. Despite market headwinds and customer destocking, management remains confident in achieving growth and margin targets for FY26 and beyond.
Fiscal Year 2025
-
FY25 combined sales reached INR 3,346 crore and adjusted EBITDA INR 402 crore, including one month from the acquired group. Management targets EUR 35 million acquired-group EBITDA in FY26 and EUR 90 million–EUR 100 million in 3–4 years, while prioritizing integration and deleveraging.
-
Q3 FY25 saw 18% revenue growth and improved margins, driven by strong export and specialty pigment sales, while RIECO turned EBITDA positive. Acquisition of Heubach is on track for March 2025, with funding secured and integration costs recognized.
-
Q2 revenue rose 13% YoY and EBITDA margin improved to 13.6%; pigment sales grew 26%, with exports up 44%. Management expects mid-teens growth and sees completed CapEx supporting international expansion.
-
Q1 FY25 saw 4% revenue growth and 15% EBITDA increase year-on-year, driven by strong specialty pigment demand and improved margins. Net debt and leverage ratios improved, while management expects sustained gross margins and operational leverage benefits.
Fiscal Year 2024
-
The debt-free acquisition adds 17 sites, 33 stock points and global reach, with closing targeted for Q1 2025 subject to approvals. Integration targets cost, manufacturing and working-capital gains, with full value capture expected over two years.